{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:29:09Z","timestamp":1785929349305,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI Grant","award":["JP19K09116"],"award-info":[{"award-number":["JP19K09116"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1245\/s10434-021-09899-8","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:02:45Z","timestamp":1617649365000},"page":"7606-7613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer"],"prefix":"10.1245","volume":"28","author":[{"given":"Kana","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-236X","authenticated-orcid":false,"given":"Yoshifumi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kameyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"9899_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin."},{"key":"9899_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1006\/gyno.1998.5145","volume":"72","author":"RE Bristow","year":"1999","unstructured":"Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278\u201387.","journal-title":"Gynecol Oncol."},{"key":"9899_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1006\/gyno.2001.6313","volume":"82","author":"SM Eisenkop","year":"2001","unstructured":"Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with \u201cbiological aggressiveness\u201d and survival? Gynecol Oncol. 2001;82:435\u201341.","journal-title":"Gynecol Oncol."},{"key":"9899_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"SJ Chang","year":"2013","unstructured":"Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. Gynecol Oncol. 2013;130:493\u20138.","journal-title":"Gynecol Oncol."},{"key":"9899_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W","volume":"88","author":"C Scarabelli","year":"2000","unstructured":"Scarabelli C, Gallo A, Franceschi S, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000;88:389\u201397.","journal-title":"Cancer."},{"key":"9899_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1006\/gyno.2001.6375","volume":"83","author":"W Jaeger","year":"2001","unstructured":"Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2001;83:286\u201391.","journal-title":"Gynecol Oncol."},{"key":"9899_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1006\/gyno.2001.6353","volume":"83","author":"A Obermair","year":"2001","unstructured":"Obermair A, Hagenauer S, Tamandl D, et al. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2001;83:115\u201320.","journal-title":"Gynecol Oncol."},{"key":"9899_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ygyno.2005.07.112","volume":"99","author":"SM Mourton","year":"2005","unstructured":"Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99:608\u201314.","journal-title":"Gynecol Oncol."},{"key":"9899_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jamcollsurg.2006.06.027","volume":"203","author":"GD Aletti","year":"2006","unstructured":"Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006;203:521\u20136.","journal-title":"J Am Coll Surg."},{"key":"9899_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jamcollsurg.2006.06.019","volume":"203","author":"JM Estes","year":"2006","unstructured":"Estes JM, Leath CA 3rd, Straughn JM Jr, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203:527\u201332.","journal-title":"J Am Coll Surg."},{"key":"9899_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.ygyno.2006.06.004","volume":"103","author":"JY Park","year":"2006","unstructured":"Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103:977\u201384.","journal-title":"Gynecol Oncol."},{"key":"9899_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ygyno.2006.05.003","volume":"103","author":"DL Richardson","year":"2006","unstructured":"Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006;103:667\u201372.","journal-title":"Gynecol Oncol."},{"key":"9899_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ygyno.2007.08.003","volume":"107","author":"R Salani","year":"2007","unstructured":"Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007;107:495\u20139.","journal-title":"Gynecol Oncol."},{"key":"9899_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ygyno.2012.04.030","volume":"126","author":"M Peiretti","year":"2012","unstructured":"Peiretti M, Bristow RE, Zapardiel I, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012;126:220\u20133.","journal-title":"Gynecol Oncol."},{"key":"9899_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1757-2215-7-72","volume":"7","author":"G Giorda","year":"2014","unstructured":"Giorda G, Gadducci A, Lucia E, et al. Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. J Ovarian Res. 2014;7:72.","journal-title":"J Ovarian Res."},{"key":"9899_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12957-016-0800-1","volume":"14","author":"P Derlatka","year":"2016","unstructured":"Derlatka P, Sienko J, Grabowska-Derlatka L, et al. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World J Surg Oncol. 2016;14:58.","journal-title":"World J Surg Oncol."},{"key":"9899_CR17","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.21873\/anticanres.11050","volume":"36","author":"CA Philip","year":"2016","unstructured":"Philip CA, Pelissier A, Bonneau C, Hequet D, Rouzier R, Pouget N. Impact of neoadjuvant chemotherapy on the rate of bowel resection in advanced epithelial ovarian cancer. Anticancer Res. 2016;36:4865\u201371.","journal-title":"Anticancer Res."},{"key":"9899_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ejso.2015.12.001","volume":"42","author":"F Plotti","year":"2016","unstructured":"Plotti F, Montera R, Aloisi A, et al. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer. Eur J Surg Oncol. 2016;42:383\u201390.","journal-title":"Eur J Surg Oncol."},{"key":"9899_CR19","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.3802\/jgo.2018.29.e60","volume":"29","author":"M Kim","year":"2018","unstructured":"Kim M, Suh DH, Park JY, et al. Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol. 2018;29:e60.","journal-title":"J Gynecol Oncol."},{"key":"9899_CR20","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3802\/jgo.2019.30.e25","volume":"30","author":"R Tozzi","year":"2019","unstructured":"Tozzi R, Casarin J, Baysal A, et al. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer. J Gynecol Oncol. 2019;30:e25.","journal-title":"J Gynecol Oncol."},{"key":"9899_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1006\/gyno.1995.0008","volume":"59","author":"KA O'Hanlan","year":"1995","unstructured":"O\u2019Hanlan KA, Kargas S, Schreiber M, et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol. 1995;59:200\u20136.","journal-title":"Gynecol Oncol."},{"key":"9899_CR22","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1245\/s10434-007-9565-7","volume":"14","author":"R Salani","year":"2007","unstructured":"Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007;14:3552\u20137.","journal-title":"Ann Surg Oncol."},{"key":"9899_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jso.21940","volume":"104","author":"G Baiocchi","year":"2011","unstructured":"Baiocchi G, Cestari LA, Macedo MP, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol. 2011;104:250\u20134.","journal-title":"J Surg Oncol."},{"key":"9899_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejso.2011.10.006","volume":"38","author":"S Gouy","year":"2012","unstructured":"Gouy S, Goetgheluck J, Uzan C, Duclos J, Duvillard P, Morice P. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer. Eur J Surg Oncol. 2012;38:170\u20135.","journal-title":"Eur J Surg Oncol."},{"key":"9899_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1477-7819-11-64","volume":"11","author":"A Di Giorgio","year":"2013","unstructured":"Di Giorgio A, Cardi M, Biacchi D, et al. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J Surg Oncol. 2013;11:64.","journal-title":"World J Surg Oncol."},{"key":"9899_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1477-7819-11-184","volume":"11","author":"K Kumagai","year":"2013","unstructured":"Kumagai K, Okamura T, Toyoda M, Senzaki H, Watanabe C, Ohmichi M. Rectal lymph node metastasis in recurrent ovarian carcinoma: essential role of 18F-FDG PET\/CT in treatment planning. World J Surg Oncol. 2013;11:184.","journal-title":"World J Surg Oncol."},{"key":"9899_CR27","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1245\/s10434-014-3558-0","volume":"21","author":"V Gallotta","year":"2014","unstructured":"Gallotta V, Fanfani F, Fagotti A, et al. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations. Ann Surg Oncol. 2014;21:2369\u201375.","journal-title":"Ann Surg Oncol."},{"key":"9899_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00404-018-4675-y","volume":"297","author":"R Berretta","year":"2018","unstructured":"Berretta R, Capozzi VA, Sozzi G, et al. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer. Arch Gynecol Obstet. 2018;297:997\u20131004.","journal-title":"Arch Gynecol Obstet."},{"key":"9899_CR29","volume-title":"AJCC cancer staging manual","year":"2017","unstructured":"Amin MB, Edge S, Greene F, et al editors. AJCC cancer staging manual. 8th edn. New York: Springer International; 2017.","edition":"8"},{"key":"9899_CR30","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-392rectal cancer (version 6. 2020). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf. Accessed 6 Nov 2020."},{"key":"9899_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ygyno.2008.09.046","volume":"112","author":"MC Lim","year":"2009","unstructured":"Lim MC, Kang S, Lee KS, et al. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol. 2009;112:28\u201334.","journal-title":"Gynecol Oncol."},{"key":"9899_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1148\/radiol.2016152595","volume":"282","author":"AC O'Neill","year":"2017","unstructured":"O\u2019Neill AC, Somarouthu B, Tirumani SH, et al. Patterns and prognostic importance of hepatic involvement in patients with serous ovarian cancer: a single-institution experience with 244 patients. Radiology. 2017;282:160\u201370.","journal-title":"Radiology."},{"key":"9899_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/gyno.2002.6717","volume":"87","author":"DS Chi","year":"2002","unstructured":"Chi DS, Temkin SM, Abu-Rustum NR, Sabbatini P, Jarnagin WR, Blumgart LH. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. Gynecol Oncol. 2002;87:138\u201342.","journal-title":"Gynecol Oncol."},{"key":"9899_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3346\/jkms.2002.17.3.415","volume":"17","author":"JH Lee","year":"2002","unstructured":"Lee JH, Kim KS, Chung CW, Park YN, Kim BR. Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. J Korean Med Sci. 2002;17:415\u20138.","journal-title":"J Korean Med Sci."},{"key":"9899_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0090-8258(03)00004-0","volume":"89","author":"MA Merideth","year":"2003","unstructured":"Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89:16\u201321.","journal-title":"Gynecol Oncol."},{"key":"9899_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12957-015-0652-0","volume":"13","author":"N Bacalbasa","year":"2015","unstructured":"Bacalbasa N, Dima S, Brasoveanu V, et al. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol. 2015;13:235.","journal-title":"World J Surg Oncol."},{"key":"9899_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.21037\/hbsn.2018.12.06","volume":"8","author":"M Wang","year":"2019","unstructured":"Wang M, Zhou J, Zhang L, et al. Surgical treatment of ovarian cancer liver metastasis. Hepatobiliary Surg Nutr. 2019;8:129\u201337.","journal-title":"Hepatobiliary Surg Nutr."},{"key":"9899_CR38","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med."},{"key":"9899_CR39","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med."},{"key":"9899_CR40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928\u201336.","journal-title":"Lancet Oncol."},{"key":"9899_CR41","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37:2317\u201328.","journal-title":"J Clin Oncol."},{"key":"9899_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-90-481-2247-9_4","volume-title":"Lymphangiogenesis in cancer metastasis: cancer metastasis\u2014biology and treatment 13","author":"M Rinderknecht","year":"2009","unstructured":"Rinderknecht M, Detmar M. Molecular mechanisms of lymph node metastasis. In: Stacker SA, Achen MG, editors. Lymphangiogenesis in cancer metastasis: cancer metastasis\u2014biology and treatment 13. Dordrecht: Springer; 2009. p. 55\u201382."},{"key":"9899_CR43","volume-title":"Robbins basic pathology","author":"V Kumar","year":"2019","unstructured":"Kumar V, Abbas AK, Aster JC. Robbins basic pathology. 10th edn. Pennsylvania: Elsevier; 2019.","edition":"10"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09899-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:10:22Z","timestamp":1634328622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09899-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["9899"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09899-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kana Tanaka, Yoshifumi Shimada, Koji Nishino, Kosuke Yoshihara, Masato Nakano, Hitoshi Kameyama, Takayuki Enomoto and Toshifumi Wakai has nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}